CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...
Phase 3
Sevilla, Spain and 77 other locations
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have ...
Phase 2, Phase 3
Seville, Spain and 82 other locations
who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, e....
Phase 1
Sevilla, Spain and 21 other locations
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Com...
Phase 2
Sevilla, Spain and 93 other locations
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....
Phase 1, Phase 2
Seville, Spain and 59 other locations
-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer...
Phase 1, Phase 2
Jeréz De La Frontera, Cádiz, Spain and 123 other locations
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial...
Phase 3
Sevilla, Spain and 165 other locations
or metastatic cancers....
Phase 1
Sevilla, Spain and 47 other locations
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....
Phase 1, Phase 2
Sevilla, Spain and 76 other locations
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial ...
Phase 2
Sevilla, Spain and 105 other locations
Clinical trials
Research sites
Resources
Legal